English
Yurogen Biosystems is an international biotechnology company founded in Boston, Massachusetts in 2015, dedicated to the discovery and development of monoclonal antibodies. In 2018, we expanded our CRO services to the East Asian market by establishing a branch in Wuhan, China. To further extend our global coverage, we merged with ABclonal Science Inc., a growing provider of biological reagents and services, in 2021.
Our state-of-the-art SMab™ platform, a single-B-cell-based monoclonal antibody development technology, has enabled us to successfully develop a variety of antibodies, including rabbit, llama, and human monoclonal antibodies, providing antibody-based solutions for scientific research, in vitro diagnostics, and antibody-related drug development applications.
Through innovative research and development, Yurogen Biosystems has become a preeminent leader in the field of customized antibody discovery, engineering, and production, serving various leading biotechnology and pharmaceutical companies in the U.S. and abroad.
QUALITY ANTIBODIES FACILITATE YOUR DISCOVERY
Yurogen Biosystem L.L.C founded in Worcester, MA, US.
Yurogen lanuched single cell-based monoclonal antibody technology
Yurogen established a Subsidiary company in Wuhan, China expanding CRO service to East Asia market.
Yurogen merged with ABclonal Technology, a leader of reagents and services in the global life sciences market.
By the end of March, Yurogen has successfully delivered 2000+ customized rabbit monoclonal antibody discovery projects
Aiming to improve the quality of people’s life, we developed SMab™ platform based on Rabbit Single B cell antibody technology and are expanding our service globally to facilitate the antibody discovery in many countries, so as to generate more novel drugs for the patients.
We will continuously work on new innovations and look forward to cooperating with you to make a meaningful difference to the world.
——Dr. Yang Lou, CEO, Yurogen Biosystems L.L.C